Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease

Next Previous
Search
Trial Profile

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Acronyms LEGATO-HD
  • Sponsors Teva Branded Pharmaceutical Products R&D

    • Most Recent Events

    • 01 Mar 2024 Results of Safety and efficacy of laquinimod , published in the Lancet Neurology
    • 16 Sep 2020 Results from of LEGATO-HD assessing whether laquinimod affect regional microglia activation in Huntingtons disease presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
    • 23 Sep 2019 According to an Active Biotech media release, data from this study will be presented at the International congress of Parkinsons disease and Movement disorders in Nice, France, September 22 to 26, 2019.The data will be presented in three posters.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top